Suppression of tumor growth by a heterologous antibody directed against multiple myeloma dominant CD38 antigen in SCID mice injected with multiple myeloma cells.

Abstract

Employing passive immunization - using a heterologous anti-CD38 IgG antibody containing serum - in SCID mice injected subcutaneously with human multiple myeloma cells, we have shown that treatments with the antiserum - especially in the presence of complement - significantly decreased cancer growth. However, administered antibody and complement was not sufficient in amount to prevent cancer cell multiplication and cancer growth expansion to a satisfactory degree. Larger volumes of the same components more than likely would have further reduced cancer growth and prolonged the life of mice. In control mice, cancer growth progressed faster proving that lytic immune response against multiple myeloma cells is necessary for cancer cell kill.

• Authors: Arpad Z Barabas, Chad D Cole, Richard M Graeff, Zoltan B Kovacs, Rene Lafreniere
• Journal: Human antibodies (Hum Antibodies) Vol. 24 Issue 3-4 Pg. 53-57 ( 2016) ISSN: 1875-869X [Electronic] Netherlands
• PMID: 28128765 (Publication Type: Journal Article)

Chemical References

• Antibodies, Monoclonal
• Cancer Vaccines
• Immune Sera
• Complement System Proteins
• ADP-ribosyl Cyclase 1

Topics

• ADP-ribosyl Cyclase 1 (genetics, immunology)
• Animals
• Antibodies, Monoclonal (administration & dosage, genetics, immunology)
• Cancer Vaccines (administration & dosage, genetics, immunology)
• Cell Line, Tumor
• Cell Proliferation
• Complement System Proteins (administration & dosage)
• Female
• Gene Expression
• Humans
• Immune Sera (administration & dosage, chemistry)
• Immunization, Passive (methods)
• Injections, Subcutaneous
• Mice
• Mice, SCID
• Multiple Myeloma (genetics, immunology, pathology, prevention & control)
• Rabbits
• Transplantation, Heterologous
• Tumor Burden